Evidence map›Paper›PMID 31878948›Full record

ArticleJournal of translational medicine2019

A spontaneously metastatic model of bladder cancer: imaging characterization.

James L Tatum, Joseph D Kalen, Paula M Jacobs, Lilia V Ileva, Lisa A Riffle, Melinda G Hollingshead, James H Doroshow

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Patient-Derived In Vitro and In Vivo Models of Cancer.Advances in experimental medicine and biology · 2022
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

James L TatumCancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Rockville, MD, USA.ORCID 0000-0002-3217-2478
Joseph D KalenSmall Animal Imaging Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID 0000-0002-7163-4604
Paula M JacobsCancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Rockville, MD, USA. jacobsp@mail.nih.gov.ORCID 0000-0002-9423-6473
Lilia V IlevaSmall Animal Imaging Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID 0000-0001-8286-8396
Lisa A RiffleSmall Animal Imaging Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.ORCID 0000-0003-3975-3088
Melinda G HollingsheadBiological Testing Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Frederick, MD, USA.ORCID 0000-0002-1207-1397
James H DoroshowDivision of Cancer Treatment and Diagnosis, and Center for Cancer Research, National Cancer Institute, National Institute of Health, Rockville, MD, USA.ORCID 0000-0002-4463-1790
Frederick National Laboratory for Cancer Research · USNational Cancer Institute · USNational Cancer Institute · MY

Funding

NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

backgroundSpontaneously metastatic xenograft models of cancer are infrequent and the few that exist are resource intensive. In xenografts, caliper measurements can be used to determine primary tumor burden and response to therapy but in metastatic disease models determination of the presence of metastatic disease, metastatic burden, and response to therapy are difficult, often requiring serial necropsy. In this study we characterized the development of visceral metastases in a patient derived xenograft model (PDXM) using in vivo imaging.

resultsWe identified and characterized the previously unreported development of spontaneous liver and bone metastasis in a known patient derived xenograft, bladder xenograft BL0293F, developed by Jackson Laboratories and the University of California at Davis and available from the National Cancer Institute Patient-Derived Models Repository [1]. Among FDG-PET/CT, contrast-enhanced MRI and non-contrast MRI, non-contrast T2w MRI was the most effective and efficient imaging technique. On non-contrast T2 weighted MRI, hepatic metastases were observed in over 70% of animals at 52 days post tumor implantation without resection of the xenograft and in 100% of animals at day 52 following resection of the xenograft. In a group of animals receiving one cycle of effective chemotherapy, no animals demonstrated metastasis by imaging, confirming the utility of this model for therapy evaluation. There was good agreement between pathologic grade and extent of involvement observed on MRI T2w imaging.

conclusionPDX BL0293F is a reliable visceral organ (liver) metastatic model with high penetrance in both non-aggravated and post excisional situations, providing a reliable window for therapy intervention prior to required excision of the xenograft. The imaging characteristics of this model are highly favorable for non-clinical research studies of metastatic disease when used in conjunction with non-contrast T2 weighted MRI.

Indexed as

Imaging, Three-DimensionalAnimalsFemaleHumansLiver NeoplasmsMagnetic Resonance ImagingMice, Inbred NODNeoplasm MetastasisUrinary Bladder NeoplasmsXenograft Model Antitumor AssaysAnimal modelBladder cancerMetastasisMRINon-clinicalPatient derived xenograft models (PDXM)

Identifiers

PMID31878948
PMCPMC6931243
OpenAlexW2996986700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.